VivoSeq
Oncology

Chronic Myeloid Leukemia (CML)

2

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Chronic Myeloid Leukemia (CML) is an early-stage landscape with 2 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Bortezomib

Shilpa Grover, MD, MPH

NK Cells

Southwest Hospital, China

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSCell therapy133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00720785·35 enrolled
Combination Study of Pioglitazone and Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia Patients After Failure of a First TKIs Discontinuation Attempt in Order to Prepare a New Stop
Recruiting·VVersailles Hospital·Phase 2·NCT02889003·26 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)